incontinence treatment device ישראל - עברית - Ministry of Health

incontinence treatment device

"a.m.i. technologies, ltd." - כלל האוכלוסיה - התקן חד פעמי סטרילי ליצירת חסימה מפני דליפת שתן

urological catheters ישראל - עברית - Ministry of Health

urological catheters

קיור מדיקל אנד טכניקל סופלאי - אחות - אביזרים שונים

urological catheters ישראל - עברית - Ministry of Health

urological catheters

קיור מדיקל אנד טכניקל סופלאי - רופא - קטטרים

urological catheters ישראל - עברית - Ministry of Health

urological catheters

אלדן ציוד אלקטרוני בע"מ - רופא - קטטרים

לוטמקס תרחיף ישראל - עברית - Ministry of Health

לוטמקס תרחיף

abic marketing ltd, israel - loteprednol etabonate - תרחיף לעין - loteprednol etabonate 5 mg / 1 ml - loteprednol - loteprednol - lotemax is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to otain an advisable diminution in edema and inflammation. lotemax is less effective than prednisolone acetate 1 % in two 28 day controlled clinical studies in acute anterior uveitis, where 72 % of patients treated with lotemax experienced resolution of anterior chamber cells, compared to 87 % of patients treated with prednisolone acetate 1 % . the incidence of patients with clinically significant increases in iop (> or = 10 mmhg) was 1 % with lotemax adn 6 % with prednisolone acetate 1 %. lotemax should not be used in patients who require a more potent corticosteroid for this indication. lotemax is also indicated for the treatment of po

אנדומטרין ישראל - עברית - Ministry of Health

אנדומטרין

ferring pharmaceuticals ltd - progesterone - טבליות וגינליות - progesterone 100 mg - progesterone - progesterone - progesterone supplementation or replacement in cases such as treatment of infertile women and ivf.

פרוברה 5 מג ישראל - עברית - Ministry of Health

פרוברה 5 מג

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - טבליה - medroxyprogesterone acetate 5 mg - medroxyprogesterone - medroxyprogesterone - in cases requiring progesterone supplement.

סיאנה ישראל - עברית - Ministry of Health

סיאנה

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - תרחיף להזרקה - medroxyprogesterone acetate 104 mg / 0.65 ml - medroxyprogesterone - medroxyprogesterone - * sayana is indicated for long-term female contraception. each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/- 1 week). however, it should be taken into consideration that the return to fertility (ovulation) may be delayed for up to one year .since loss of bone mineral density may occur in females of all ages who use sayana long-term, a risk/benefit assessment, which also takes into consideration the decrease in bone mineral density that occurs during pregnancy and/or lactation, should be considered.* use in adolescents (12-18 years)in adolescents, use of sayana is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with sayana during the critical period of bone accretion.sayana has not been studied in women under the age of 18 years but data is available for intramuscular medroxyprogesterone acetate in this population.

אוטרוגסטן 200 ישראל - עברית - Ministry of Health

אוטרוגסטן 200

cts ltd - progesterone micronized - קפסולות - progesterone micronized 200 mg - progesterone - progesterone - vaginal administration: progesterone substitution for ovary deprived women in situation of total progesterone deficiency. supplementation of the luteal phase during in vitro fertilization cycles. supplementation of the luteal phase during spontaneous or induced cycles, in cases of hypofertility or primary or secondary ovarain failure, particulary through dysovulation. in cases of threatning abortion or prevention of repeated abortions due to proven luteal insufficiency. for all other progesterone indication, in the case of : adverse events due to progesterone, contraindication of the oral route of administration hepatopathy. vaginal or oral addministration: disorders related to progesterone deficit in particular menopause ( in association with estrogen therapy).